Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raptiva in Palmoplantar Psoriasis
NCT00972543Phase 4Terminated
- Sponsor
- Merck KGaA
- Start
- Sep 2008
- Primary completion
- May 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 4 trial of efalizumab in plaque psoriasis, sponsored by Merck KGaA. Started Sep 2008; status: terminated.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00972543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00972543.